Phaseline

Companies › RenovoRx

RenovoRx: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RenovoCath
Intra-arterial catheter delivery device
–Phase 3Locally Advanced Pancreatic CancerJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03257033RenovoCathPhase 3Locally Advanced Pancreatic CancerOncologyJun 2027

From the company's SEC filings

Cash of $10m on 2026-09-30; operating cash outflow about $12m a year; runway about 10 months at that burn, to Aug 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Can-Fite BioPharma LeonaBio Intensity Therapeutics Angiodynamics Aura Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.